Health and Healthcare
Why This Analyst Sees Big Upside in COVID-19 Immunotherapy Study
Published:
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) made a big splash on Tuesday by announcing that it would initiate an early-stage immunotherapy study in patients with COVID-19. This incredible move caught the attention of one key analyst, who sees this stock running much higher.
Corvus initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. This comes after the U.S. Food and Drug Administration’s (FDA) review and acceptance of the firm’s investigational new drug (IND) application for the COVID-19 study.
Wedbush reiterated an Outperform rating and raised its price target to $8 from $5, which implies an upside of 53% from the most recent closing price of $5.22.
Wedbush believes that this treatment with CPI-006 could be a compelling strategy to generate robust humoral adaptive immune responses and improve clinical outcome in COVID-19 patients, based on the presented data and given high antiSARS2-CoV-2 antibody titers demonstrated in a recently enrolled patient with COVID-19 with a number of comorbidities.
Although the use of convalescent serum as a therapeutic option for COVID-19 is further along clinically with positive case reports, the boutique brokerage firm believes CPI-006 could be a highly complementary approach. More importantly, it could actually increase the magnitude of the response achieved by recovered patients.
Additionally, Wedbush sees CPI-006 as potentially representing a more accessible approach in the treatment setting versus convalescent plasma therapy, due to scalability challenges of the serum approach.
Look for initial data from Corvus’s COVID-19 Phase 1 study later this year.
Corvus Pharmaceuticals stock traded up about 9% on Wednesday to $5.39, in a 52-week range of $1.01 to $6.88. The consensus price target is $9.20.
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
